Monday, February 4, 2019 Daily Archives

Pfizer looks to oncology biosimilars to break US market

by

Biosimilar uptake in the US has been stifled in the inflammation and immunology (I&I) space but Pfizer expects a different dynamic for oncology products. Pfizer’s biosimilar business had a robust year in 2018. The firm reported a 41% operational growth in the sector over the year prior, with total sales of $769 million (€674 million). The company attributed much of this growth to sales of Inflectra, its version of J&J’s Remicade (infliximab), which pulled in $642 million worldwide including $259…

February 4, 2019

Novo Nordisk DKK 9bn CapEx in 2019 ‘higher than expected’

by

Novo Nordisk spent $1.5 billion on CapEx in 2018 and expects to pay a further $1.4 billion in 2019 driven by investment in drug substance at its North Carolina site. Danish drugmaker Novo Nordisk had a flat year in 2018, pulling in sales of DKK 112 billion ($17 billion). Net profit remained relatively constant too, with the firm reporting DKK 39 billion ($6 billion). According to CFO Karsten Munk Knudsen, “manufacturing had a fantastic year in 2018. He told stakeholder:…

February 4, 2019